Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

January 8, 2024

https://www.globenewswire.com/news-release/2024/01/08/2805447/11676/en/Veru-Submits-IND-Application-to-FDA-for-the-Development-of-Enobosarm-to-Prevent-Muscle-Loss-While-Augmenting-Fat-Loss-in-Combination-with-GLP-1-Drugs-for-Weight-Loss.html

MIAMI, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for the development of enobosarm for obesity.

Read more at globenewswire.com

Related news for (VERU)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.